#302 - Confronting a metabolic epidemic: understanding liver health and how to prevent, diagnose, and manage liver disease | Julia Wattacheril, M.D., M.P.H.
Dr. Julia Wattacheril, a transplant hepatologist and director of Columbia's MASLD program, details liver physiology, the impact of alcohol and metabolic dysfunction on liver health, and strategies for diagnosing, treating, and preventing disease progression. She emphasizes early diagnosis and understanding the broader cardiometabolic and oncologic risks.
Deep Dive Analysis
19 Topic Outline
Hepatologist's Role and Liver's Essential Functions
Evolution of Liver Disease and Transplantation History
Acute vs. Chronic Liver Injury and Transplant Indications
Viral Hepatitis B and C: Cancer Risk and Treatment
Liver Metabolism: Nutrient Handling and Fat Accumulation
Diagnosing Hepatic Steatosis: Imaging Modalities
Alcohol Metabolism, Toxicity, and Counseling Patients
Interpreting Liver Enzymes: AST, ALT, and GGT
Comprehensive Liver Health Assessment and Risk Factors
Impact of Recreational Drugs and Medications on Liver
Nomenclature Shift: From NAFLD/NASH to MASLD
Pathophysiology and Prevalence of MASLD
Identifying Rare Liver Conditions (Zebras)
Lifestyle Interventions for MASLD Management
Fructose and Coffee's Role in Liver Health
GLP-1 Agonists for MASLD Treatment
Staging and Reversibility of Liver Fibrosis and Cirrhosis
Cancer and Cardiovascular Risks in Early-Stage MASLD
Emerging Drug Therapies for MASLD
8 Key Concepts
Extracorporeal Support
Artificial systems that temporarily perform organ functions outside the body. The liver lacks effective extracorporeal support, highlighting its immense complexity and essential nature, as there's no bridge to transplantation for acute liver failure.
Hepatocytes
The primary liver cells, making up about 80% of the liver. These cuboidal or hexagonal cells are responsible for most liver functions and contain enzymes like AST and ALT, which are released into the bloodstream when the cells are stressed or damaged.
Acetaldehyde Toxicity
Acetaldehyde is an intermediary metabolite produced when the liver processes alcohol. When the liver's capacity to metabolize alcohol is overwhelmed, acetaldehyde accumulates, becoming pro-inflammatory, attracting free radicals, and leading to liver cell damage and altered metabolism.
Steatosis
The accumulation of fat within the liver, diagnostically defined as more than 5% of hepatocytes containing fat. It is an early indicator of liver dysfunction, often resulting from nutrient excess overwhelming the liver's processing and storage capabilities.
Fibrosis
The medical term for scar tissue in the liver, which is a key metric for assessing liver injury progression. Fibrosis is staged from 1 to 4, with stage 4 being cirrhosis, indicating significant architectural disruption and nodule formation.
Vibration-Controlled Transient Elastography (VCTE)
A point-of-care ultrasound-based technology, often known by the proprietary name FibroScan, used to non-invasively measure both liver fat (via Controlled Attenuation Parameter, CAP) and liver stiffness (elastography). It provides a fat score and a scar score, which are crucial for early detection and monitoring.
MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease)
The new umbrella term replacing NAFLD/NASH, defined as liver fat accumulation driven by metabolic dysfunction. This change addresses patient stigma and more accurately reflects the underlying cardiometabolic pathophysiology, which can overlap with alcohol consumption (MET-ALD).
Hepatocellular Carcinoma (HCC)
The primary liver cancer that originates in the liver. Its risk is generally associated with cirrhosis for most liver diseases, but notably, it can develop in individuals with chronic hepatitis B independent of their degree of scar tissue.
11 Questions Answered
The liver is an essential organ with over 300 functions, including metabolism, immune function, detoxification, and synthetic protein production, for which no effective extracorporeal support exists, highlighting its irreplaceable role in the body.
Historically, toxins like alcohol and infectious agents, particularly viral hepatitis (e.g., non-A, non-B, which became Hepatitis C), were the predominant drivers of liver injury and the main indications for early liver transplantation.
Alcohol is metabolized into acetaldehyde, which, when in excess, becomes pro-inflammatory, attracts free radicals, and overwhelms the liver cell's redox potential, leading to cellular damage, fat deposition, and altered metabolism.
AST and ALT are enzymes released into the bloodstream when liver cells (hepatocytes) are under stress or dying, serving as markers of necroinflammation rather than direct measures of the liver's overall function.
Standard ultrasounds are often insensitive, requiring over 30% fat for detection. More accurate methods include MRI-PDFF (proton density fat fraction) or point-of-care vibration-controlled transient elastography (VCTE) with a controlled attenuation parameter (CAP).
The change was driven by patient feedback regarding the stigmatizing nature of 'non-alcoholic' and 'fatty,' and to better reflect the underlying metabolic dysfunction pathophysiology, which often involves cardiometabolic risk factors.
Approximately 25% to 35% of the U.S. population, and globally, may have MASLD, often without their knowledge, making it the most common liver disease.
Comprehensive lifestyle changes, including regular exercise (aerobic and resistance), adequate sleep, and nutrition focused on reducing processed foods and refined carbohydrates, are critical for improving MASLD.
Yes, GLP-1 agonists like semaglutide and tirzepatide are highly effective in treating MASLD due to their profound impact on weight loss and insulin sensitivity, with recent phase three data showing promise for liver-related outcomes.
Traditionally considered irreversible, new understanding, especially after hepatitis C cures, suggests that early cirrhosis (stage 4 scarring) can show evidence of reversibility, offering hope for patients with advanced disease.
For individuals with early-stage MASLD, the immediate risks of cardiovascular disease and other malignancies (e.g., diabetes, certain cancers) often outweigh the near-term risk of liver-related mortality, highlighting the systemic impact of metabolic dysfunction.
29 Actionable Insights
1. Target ALT/AST Under 30
Aim for AST and ALT levels under 30 for optimal liver health, rather than just within the lab’s ’normal’ range (often 40-50). Persistent elevations in the 50s and 60s (1.5-2x upper limit) warrant investigation.
2. Don’t Trust Basic Ultrasound
Do not rely on a plain old ultrasound to rule out hepatic steatosis, as it generally only detects fat levels above 30%. Consider more sensitive imaging like MRI-PDFF or vibration-controlled transient elastography for accurate diagnosis.
3. Aminotransferases Poor Early Marker
Do not rely solely on aminotransferases (AST/ALT) as an early indicator of liver injury, especially from alcohol or steatosis, as they only elevate with significant derangement. Consider bedside imaging like vibration-controlled transient elastography for earlier detection of hepatic steatosis.
4. Utilize Advanced Liver Imaging
For accurate liver assessment, consider advanced imaging like Vibration-Controlled Transient Elastography (VCTE/FibroScan) or MRI with elastography. These methods provide both a fat score and a scar (stiffness) score, which are crucial for diagnosis and monitoring.
5. High Liver Fat Predicts Diabetes
If you have a high liver fat score (CAP score) but normal scarring, recognize this as a strong predictor for developing diabetes. Lifestyle changes can normalize fat scores within 6 weeks to 6 months and significantly reduce diabetes risk.
6. Liver Fat Is Modifiable
Understand that liver fat (steatosis) is highly modifiable through lifestyle changes like reducing alcohol intake and achieving modest weight loss. Significant improvement in fat scores can be seen within weeks to months.
7. Focus on Health Fundamentals
Focus on the foundational pillars of good health: consistent exercise, adequate sleep, and balanced nutrition. These are the most important tools for improving overall metabolic health, including liver function.
8. Increase Resistance Training
Incorporate resistance training into your exercise routine, especially for women and as you age, to build muscle mass. Combine aerobic and resistance activities to improve metabolic health and combat sarcopenia.
9. Coffee Benefits Liver Health
Consider consuming up to three cups of black coffee daily for potential liver benefits, including anti-fibrotic and good metabolic effects. This is supported by multiple studies and included in some guidelines, though it’s not a prescription.
10. Avoid Processed Foods First
Instead of focusing on eliminating single nutrients like fructose, prioritize avoiding processed foods for dietary improvement. This is a more implementable and less distressing strategy for most people.
11. Detect Early Insulin Resistance
Monitor for early insulin resistance using metrics like HOMA-IR or glucose tolerance tests to identify the window for intervention before overt hyperglycemia. This allows for proactive management of metabolic health.
12. Screen Liver Disease Risk Factors
Screen for liver disease risk by evaluating metabolic health (BMI, metabolic syndrome, cardiometabolic factors), lifestyle habits (exercise, nutrition), and calculating FIB-4 scores for individuals over 50, especially if male or diabetic. These factors indicate a need for secondary testing.
13. Understand Standard Drink Sizes
Learn and adhere to standard drink definitions (1.5 oz liquor, 5 oz wine, 12 oz beer) to accurately quantify alcohol intake. Many people unknowingly consume more than a ‘standard’ drink.
14. Rest Before Liver Blood Test
Be aware that intense exercise can elevate AST and ALT levels; consider drawing blood on a rest day or after more than 24 hours of no exercise for a more accurate liver enzyme assessment. This helps avoid misinterpretation of results.
15. Investigate Atypical Liver Fat
If a patient has high hepatic fat but lacks typical metabolic risk factors or elevated circulating triglycerides, clinicians should investigate rarer causes like genomic familial hyperlipidemia or export problems. This helps identify specific, non-standard conditions.
16. Hepatitis B Cancer Screening
Screen for liver cancer in individuals with chronic, untreated hepatitis B, regardless of their degree of scar tissue or cirrhosis. This is crucial due to its unique oncologic potential, even without advanced fibrosis.
17. Cirrhosis Needs Monitoring, Not Doom
Understand that a cirrhosis diagnosis (stage four scarring) is not a death sentence or automatic transplant indication, but rather a call for increased monitoring. Early cirrhosis can even be reversible, offering hope for intervention.
18. Recognize Mixed Liver Disease
Be aware that metabolic dysfunction and even moderate alcohol use can combine to impact steatohepatitic pathways. Many individuals may have a mixed form of liver disease, requiring a comprehensive assessment of both factors.
19. Assess Holistic Health Risks
When evaluating health, consider the leading risks to overall mortality and quality of life, not just liver-specific issues. For early-stage MAFLD, cardiovascular and cancer risks often outweigh immediate liver risks.
20. Empower with Measurable Health Data
Empower patients by providing clear, measurable health information, such as scan results showing modifiable fat scores. Frame this data as an opportunity to change risk (e.g., for diabetes) and partner with them on sustainable lifestyle modifications.
21. Early Liver Disease is Reversible
Understand that early-stage liver disease is highly treatable and reversible with intervention. Seek diagnosis and address it proactively, as there’s no reason to remain unaware of its presence.
22. Beware Supplement Liver Injury
Be cautious with supplement use, as contaminated or unknown supplements can cause liver injury. Quantify exactly what’s in any supplement you take and be aware of potential risks.
23. Discuss Vitamin E Supplement Risks
Before taking vitamin E supplements, discuss potential downsides with a clinician, including increased all-cause mortality, cardiovascular risk, and prostate cancer risk, especially at higher doses or in certain populations. This ensures informed decision-making.
24. Test for Choline Deficiency
If there’s suspicion of choline deficiency, especially in individuals post-bypass surgery or with malnutrition-related steatotic liver disease, consider specific assays to measure choline levels. This helps identify and address a specific nutritional cause.
25. Don’t Assume NAFLD Instantly
When an imaging abnormality suggests hepatic steatosis, avoid a knee-jerk diagnosis of NAFLD/MASLD. Always consider alcohol as the primary differential and evaluate for rarer biochemical causes before concluding it’s purely metabolic.
26. Negative Tests Not Full Guarantee
Understand that a battery of negative tests does not guarantee future health or absence of underlying issues. Maintain humility and consider ongoing monitoring, especially for complex conditions like liver disease.
27. Comprehensive Proactive Liver Check
For proactive liver health, assess metabolic risks (BMI, metabolic syndrome factors), lifestyle habits (recreational drugs, exercise, nutrition), and current medications. This comprehensive approach helps identify potential risk factors beyond alcohol.
28. Address Patient Misinformation
For clinicians, use patient misinformation as an opportunity to educate and improve communication about health topics. This helps bridge knowledge gaps and better inform patients.
29. Support Ad-Free Health Content
Become a member to support ad-free content and gain access to exclusive benefits. This helps fund high-quality health and wellness information, enabling continued provision of valuable content.
6 Key Quotes
The liver is this essential organ for which we don't have extracorporeal support.
Peter Attia
The liver was never designed to store fat.
Julia Wattacheril
A negative ultrasound does not mean that you don't have hepatic steatosis.
Julia Wattacheril
Aminotransferases... are not functional. They're markers of injury.
Julia Wattacheril
For the most part, the average person you're seeing with MAFLD is much more at risk for cardiovascular-related outcomes and malignancy-related outcomes from their metabolic health than they are for liver-related risks.
Julia Wattacheril
Even with cirrhosis, you need to undergo some appropriate screening, but the timeline for that is not you're going to need a transplant in two years.
Julia Wattacheril